Portnoy Law Firm Announces Class Action on Behalf of MoonLake Immunotherapeutics, Inc. Investors

Core Viewpoint - MoonLake Immunotherapeutics, Inc. is facing a class action lawsuit for investors who purchased securities during the specified class period, indicating potential corporate wrongdoing [1][3]. Company Overview - MoonLake is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Drug Development - SLK's commercial prospects hinge on its ability to demonstrate efficacy in HS that is comparable or superior to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for the same indication [3].